JP2011505146A - タンパク質チロシンキナーゼ７（ｐｔｋ７）を対象とするモノクローナル抗体−パートナー分子複合体 - Google Patents

タンパク質チロシンキナーゼ７（ｐｔｋ７）を対象とするモノクローナル抗体−パートナー分子複合体 Download PDF

Info

Publication number
JP2011505146A
JP2011505146A JP2010536185A JP2010536185A JP2011505146A JP 2011505146 A JP2011505146 A JP 2011505146A JP 2010536185 A JP2010536185 A JP 2010536185A JP 2010536185 A JP2010536185 A JP 2010536185A JP 2011505146 A JP2011505146 A JP 2011505146A
Authority
JP
Japan
Prior art keywords
antibody
seq
cancer
human
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010536185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505146A5 (enExample
Inventor
ジョナサン・エイ・テレット
チン・パン
チェタナ・ラオ−ナイク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2011505146A publication Critical patent/JP2011505146A/ja
Publication of JP2011505146A5 publication Critical patent/JP2011505146A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2010536185A 2007-11-30 2008-11-26 タンパク質チロシンキナーゼ７（ｐｔｋ７）を対象とするモノクローナル抗体−パートナー分子複合体 Withdrawn JP2011505146A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US503407P 2007-11-30 2007-11-30
PCT/US2008/084949 WO2009073546A2 (en) 2007-11-30 2008-11-26 Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)

Publications (2)

Publication Number Publication Date
JP2011505146A true JP2011505146A (ja) 2011-02-24
JP2011505146A5 JP2011505146A5 (enExample) 2012-02-02

Family

ID=40718460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010536185A Withdrawn JP2011505146A (ja) 2007-11-30 2008-11-26 タンパク質チロシンキナーゼ７（ｐｔｋ７）を対象とするモノクローナル抗体−パートナー分子複合体

Country Status (11)

Country Link
US (1) US20120027782A1 (enExample)
EP (1) EP2229187A2 (enExample)
JP (1) JP2011505146A (enExample)
KR (1) KR20100101124A (enExample)
CN (1) CN101939028A (enExample)
AR (1) AR069903A1 (enExample)
AU (1) AU2008334076A1 (enExample)
CL (1) CL2008003527A1 (enExample)
MX (1) MX2010005966A (enExample)
TW (1) TW200938223A (enExample)
WO (1) WO2009073546A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517842A (ja) * 2011-05-26 2014-07-24 ブリストル−マイヤーズ スクイブ カンパニー 免疫コンジュゲート、それらを含有する組成物、ならびに製造方法および使用方法
JP2017500299A (ja) * 2013-12-19 2017-01-05 シアトル ジェネティックス， インコーポレイテッド 標的化薬物結合体と使用するためのメチレンカルバメートリンカー
JP2024531379A (ja) * 2021-08-18 2024-08-29 ナノマブ テクノロジー リミテッド 抗ｐｔｋ７単一ドメイン抗体およびその応用

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1957539B1 (en) 2005-12-08 2013-04-17 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN106967062A (zh) 2008-11-03 2017-07-21 辛塔佳股份有限公司 新型cc‑1065类似物及其缀合物
PT3056203T (pt) 2010-04-21 2018-02-15 Syntarga Bv Conjugados de análogos de cc-1065 e ligantes bifuncionais
EP2380909A1 (en) * 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
AU2012296951B2 (en) * 2011-08-12 2016-09-15 Ascendis Pharma A/S Protein carrier-linked prodrugs
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN105899235B (zh) 2014-01-10 2019-08-30 斯索恩生物制药有限公司 用于纯化cys连接的抗体-药物缀合物的方法
SG11201608953WA (en) 2014-04-30 2016-11-29 Pfizer Anti-ptk7 antibody-drug conjugates
ES2901705T3 (es) 2014-06-06 2022-03-23 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos
RS60998B1 (sr) 2014-11-21 2020-11-30 Bristol Myers Squibb Co Antitela koja sadrže modifikovane regione teškog lanca
SI3221363T1 (sl) 2014-11-21 2020-09-30 Bristol-Myers Squibb Company Protitelesa proti CD73 in njihova uporaba
CA2971732A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US11685787B2 (en) 2017-05-16 2023-06-27 Bristol-Myers Squibb Company Treatment of cancer with anti-GITR agonist antibodies
IL270596B1 (en) 2017-05-25 2025-09-01 Bristol Myers Squibb Co Antibodies comprising modified heavy constant region for use in treating cancer
CN113260384A (zh) 2018-11-05 2021-08-13 西纳福克斯股份有限公司 用于靶向表达trop-2的肿瘤的抗体缀合物
CN110845480B (zh) * 2019-11-22 2022-03-15 荣昌生物制药(烟台)股份有限公司 一种双功能细胞毒素及其用途
US20250340670A1 (en) * 2020-07-16 2025-11-06 UIF, (University Industry Foundation), Yonsei University Antibody specifically binding to ptk7 and use thereof
JP2025510623A (ja) * 2022-03-23 2025-04-15 シンアフィックス ビー．ブイ． Ｐｔｋ７を発現する腫瘍を標的化するための抗体コンジュゲート
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease
WO2024054030A1 (ko) * 2022-09-06 2024-03-14 연세대학교 산학협력단 항-ptk7 항체 및 이의 용도
CN118852442A (zh) * 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
WO2025040588A1 (en) * 2023-08-18 2025-02-27 Oncoinvent As Monoclonal anti-ptk7 antibodies and derivatives
WO2025072406A1 (en) * 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1423110A4 (en) * 2001-09-07 2005-04-27 Scripps Research Inst CBI ANALOGUE OF CC-1065 AND DUOCARMYCINES
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
EP1747021B1 (en) * 2004-05-19 2015-09-09 E. R. Squibb & Sons, L.L.C. Self-immolative linkers and drug conjugates
EP2354163A3 (en) * 2005-09-26 2013-04-24 Medarex, Inc. Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies
EP1957539B1 (en) * 2005-12-08 2013-04-17 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517842A (ja) * 2011-05-26 2014-07-24 ブリストル−マイヤーズ スクイブ カンパニー 免疫コンジュゲート、それらを含有する組成物、ならびに製造方法および使用方法
JP2017128571A (ja) * 2011-05-26 2017-07-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫コンジュゲート、それらを含有する組成物、ならびに製造方法および使用方法
JP2017500299A (ja) * 2013-12-19 2017-01-05 シアトル ジェネティックス， インコーポレイテッド 標的化薬物結合体と使用するためのメチレンカルバメートリンカー
JP2019081813A (ja) * 2013-12-19 2019-05-30 シアトル ジェネティックス， インコーポレイテッド 標的化薬物結合体と使用するためのメチレンカルバメートリンカー
JP2020152733A (ja) * 2013-12-19 2020-09-24 シアトル ジェネティックス， インコーポレイテッド 標的化薬物結合体と使用するためのメチレンカルバメートリンカー
JP7229202B2 (ja) 2013-12-19 2023-02-27 シージェン インコーポレイテッド 標的化薬物結合体と使用するためのメチレンカルバメートリンカー
JP2023055973A (ja) * 2013-12-19 2023-04-18 シージェン インコーポレイテッド 標的化薬物結合体と使用するためのメチレンカルバメートリンカー
JP2024531379A (ja) * 2021-08-18 2024-08-29 ナノマブ テクノロジー リミテッド 抗ｐｔｋ７単一ドメイン抗体およびその応用

Also Published As

Publication number Publication date
CL2008003527A1 (es) 2009-10-09
AR069903A1 (es) 2010-03-03
KR20100101124A (ko) 2010-09-16
CN101939028A (zh) 2011-01-05
EP2229187A2 (en) 2010-09-22
US20120027782A1 (en) 2012-02-02
WO2009073546A3 (en) 2009-12-30
TW200938223A (en) 2009-09-16
WO2009073546A2 (en) 2009-06-11
AU2008334076A1 (en) 2009-06-11
MX2010005966A (es) 2010-06-15

Similar Documents

Publication Publication Date Title
US20120027782A1 (en) Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)
US8865875B2 (en) Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
US8383779B2 (en) Human antibodies that bind mesothelin, and uses thereof
US20110085970A1 (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
JP2010513303A (ja) Ｃｄ１９に結合するヒト抗体およびその使用
US20090162372A1 (en) Fibronectin ed-b antibodies, conjugates thereof, and methods of use
US20110020329A1 (en) Conjugates of anti-rg-1 antibodies
HK1140943B (en) Human antibodies that bind mesothelin, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111125

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120803